Compare WPRT & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WPRT | GRML |
|---|---|---|
| Founded | 1995 | N/A |
| Country | Canada | United States |
| Employees | N/A | 5 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 34.9M |
| IPO Year | 2006 | 2022 |
| Metric | WPRT | GRML |
|---|---|---|
| Price | $1.77 | $0.19 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.38 | N/A |
| AVG Volume (30 Days) | 65.4K | ★ 7.7M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $0.16 |
| 52 Week High | $3.88 | $0.55 |
| Indicator | WPRT | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 41.58 |
| Support Level | $1.57 | $0.16 |
| Resistance Level | $1.85 | $0.30 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 35.48 | 23.95 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three reportable segments: High-Pressure Controls, Heavy-Duty OEM, and Cespira. It derives maximum revenue from Heavy-Duty OEM segment. Heavy-Duty OEM segment's products include HPDI related fuel system solutions and components. Geographically, the company operates in Europe, America and Asia, of which it generates maximum revenue from Europe. It also develops and supplies advanced LPG, CNG, LNG and H2 systems and components for OEM (original equipment manufacturer) D-OEM (delayed oem) and After Market (retrofit market) world-wide.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.